Emergent BioSolutions | EBS - Operating Expenses


Emergent BioSolutions reported $555.9M in Operating Expenses for its fiscal quarter ending in June of 2023.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
ALKERMES USD 326.44M 1.41B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.48M 113K Dec/2025
ANI Pharmaceuticals USD 217.93M 287.88M Dec/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Exelixis USD 362.75M 21.35M Dec/2025
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Merck USD 10.16B 558M Dec/2025
Moderna USD 1.54B 259M Dec/2025
Myriad Genetics USD 212.8M 16.2M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Pacira USD 193.68M 27.32M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Sanofi EUR 9.31B 1.2B Mar/2026
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
United Therapeutics USD 804.8M 5.79B Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025
Xoma USD 22.84M 1.67M Sep/2024